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Percutaneous approaches, such as percutaneous ethanol
injection and radiofrequency ablation, have been most widely
used for hepatocellular carcinoma patients who were not
eligible for surgery. New technologies to improve the efficacy
are currently needed. 166Holmium is a neutron activated radio-
nuclide, and has several beneficial radiophysical characteristics
for internal radiation therapy. 166Holmium-Chitosan complex,
in which chitosan is chelated with 166Holmium, was developed
as a radiopharmaceutical for cancer therapy. We have con-
ducted a pilot study to evaluate the clinical efficacy of transar-
terial administration of 166Holmium-Chitosan complex in pa-
tients with a single and small (< 3 cm) hepatocellular carci-
noma. 166Holmium-Chitosan complex, at a dose of 20 mCi per
cm of tumor mass-diameter, was administered through the
artery that directly fed the tumor. Twelve patients were treated
with a median follow-up duration of 26 (range: 12-61) months.
The tumor diameter ranged between 1.5 and 2.5 cm. Ten
patients (83%) had complete response and two (17%) had
partial response. The median complete response duration was
not reached. The median AFP level declined from 83.8 to 8.3
ng/mL within 2 months after treatment. No grade III/IV
toxicity was observed. Grade I and II toxicities were observed
in four patients (2 abdominal pain, 1 fever, and 1 AST/ALT
elevation). No toxic death occurred. This preliminary study
shows a promising and durable complete response rate with
an acceptable safety profile. Further studies with greater
accrual of patients are warranted.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a major
cause of morbidity and mortality worldwide.1
Percutaneous approaches, such as percutaneous
ethanol injection and radiofrequency ablation,
have been most widely used for hepatocellular
carcinoma patients who were not eligible for
surgery.1 Results in large series have demon-
strated that complete tumor necrosis can be
achieved in approximately 80 to 90% of cases.2,3
These procedures are now considered the gold
standard for patients with HCC smaller than 3
cm, who refused or were poor candidates for
surgery. However, percutaneous treatments re-
quire several treatment sessions to achieve high
response rate, and do not provide outcomes com-
parable to surgical treatments.
Internal radiation therapy using
166
Holmium
(166Ho) is a unique cancer treatment modality.4-6
166
Ho is a neutron activated radionuclide derived
from natural 165Holmium, and has several benefi-
cial radiophysical characteristics for internal radia-
tion therapy; it has an appropriate half-life of 26.8
h, a high beta-energy (1.85 MeV), and a low gam-
ma-energy (0.08 MeV) that is readily detectable by
gamma camera. The radioactive 166Ho loaded poly
(L-lactic acid) microsphere has been investigated
in several pre-clinical studies, and results have
indicated its potential as a internal radiation
therapy for HCC.4-6
Chitosan, the carrier of 166Ho in this study, is a
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polymer of 2-deoxy-2-amino-D-glucose with -1,4β
bonds; it is derived by alkaline deacetylation of
chitin obtained from living crustacean exoskele-
tons, such as crab shells, shrimps, or cuttlebone.
Previous studies have demonstrated that chitosan
is non-toxic and bio-absorbable, and has excellent
biocompatibility.7,8 166Holmium-Chitosan complex,
in which chitosan is chelated with 166Ho, was de-
veloped as a radiopharmaceutical for cancer ther-
apy by the Korea Atomic Energy Research Insti-
tute (Daejeon, Korea) and Dong Wha Pharmaceu-
tical Company (Kyunggi-do, Korea). Direct admi-
nistration of the 166Holmium-Chitosan complex
into the neutral or basic conditions of a tissue
lesion converts the solution into a gel form, and
the radioactivity of 166Ho destroys the tumor.9 We
have previously reported trans-arterial adminis-
tration of 166Holmium-Chitosan complex as a
novel and effective modality in the treatment of
single and large (tumor size 3 cm in diameter)
HCC.10
Under these backgrounds, we have conducted
a pilot study to evaluate the clinical efficacy of
trans-arterial administration of the 166Holmium-
Chitosan complex in patients with a single and
small (< 3 cm) HCC who refused or were poor
candidates for surgery.
MATERIALS AND METHODS
Patients
A clinical diagnosis of HCC was established by
concomitant positive findings on two out of three
imaging techniques, including liver spiral CT,
dynamic MRI, and hepatic artery angiography, or
by a single positive imaging technique showing
hypervascularization associated with an AFP
level greater than 400 ng/ml in patients who had
at least one risk factor for HCC, such as liver
cirrhosis, positive HBV or HCV. Inclusion criteria
included: (a) Single HCC < 3 cm; (b) patients
who refused or were poor candidates for surgery;
(c) ECOG 0-2; (d) an adequate hematologic
(neutrophil count 1,500/ L, platelet countμ
100,000/ L), renal function (serum creatinineμ
level 1.5 times the upper normal limit), liver
function (AST and ALT 5 times the upper
normal limit, bilirubin 4.0 mg/dL), and clot-
ting profile (prothrombin time 60%); and (f) an
expected survival of at least 3 months. Exclusion
criteria included: (a) arterio-portal or arterio-
venous shunt on angiography; (b) portal vein
thrombosis; (c) prior history of upper abdomen
radiation; (d) chemotherapy within the 4 weeks
prior to our treatment; (e) pregnant or lactating
women; and (f) uncontrolled cardiac, pulmonary,
or infectious disease. Informed consent was
obtained from all patients at the time of enroll-
ment.
Preparation of 166Holmium-Chitosan complex
Holmium solution [166Ho(NO3)3 5H2O] was ob-
tained from the Korea Atomic Energy Research
Institute (Daejeon, Korea); 165Ho was converted to
166Ho in a nuclear reactor at a neutron flux of 1
× 1013 n cm-1 sec-1. Chitosan was prepared by the
Pharmaceutical Development Lab (Dong Wha
Pharm Ind. Co., Ltd., Anyang, Korea) and lyophi-
lized before use by evaporation of acetic acid sol-
vent; its molecular weight was 700,000. 166Holmi-
um-Chitosan complex was formed by chemical
reaction under a pH 3 solution state. On the day
of use, 166Holmium-Chitosan complex was pre-
pared by mixing the holmium and chitosan solu-
tions.
Dose estimation
The delivery dose to the hepatoma was esti-
mated by the Monte Carlo simulation using
EGS4.
11 166
Ho was assumed to be uniformly dis-
tributed inside the tumor by intra-arterial injec-
tion. The surrounding normal tissue was assumed
to be source free. Table 1 shows the dose values
averaged over the whole tumor volume (mean
dose), the outer spherical shell of 0.25 mm thick-
ness (peripheral dose), and the remaining inner
sphere (central dose). The central dose ranged
from 112 to 120% of the mean dose, whereas the
peripheral dose ranged from 88 to 92%.
Procedures and follow-up
Selective hepatic angiography was performed
by the Seldinger technique. After microcatheter
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introduction into the super-selected artery that fed
the tumor, we slowly injected the 166Holmium-
Chitosan complex, at a dose of 20 mCi/mL (740
MBq) per cm of tumor diameter. NaHCO3
(sodium bicarbonate) was empirically adminis-
tered in an effort to maintain serum alkalization
and thus reduce the leaching of the complex into
the systemic circulation. Peripheral blood (5 mL)
was taken 15 minutes post procedure to measure
radioactivity using a beta ray counter. Whole
body and liver images were obtained using an
ADAC Genesys gamma camera (ADAC Labora-
tories, Milpitas, USA) immediately after, and also
24 hours post procedure, to analyze the complex
distribution. Hydration and G-CSF support was
performed at the physician's discretion, depen-
ding on the serum beta radiation concentration
level. Blood studies (CBC with differential, serum
creatinine, AST, ALT, total bilirubin, electrolyte,
calcium, phosphorus, total protein and albumin)
were performed daily for the first five days after
radiation, and also on days 28 and 60; urine pH
was assessed daily for the first three days for
serum alkalization. Liver spiral CT scan and/or
angiography as well as AFP levels were assessed
4 and 8 weeks after the procedure to evaluate
response. Thereafter, repeat CT scan was perfor-
med every 3 to 4 months.
Evaluation of response and further treatments
Response evaluation was performed by either
liver spiral CT scan or angiography, and was
based on the worst of the two findings. Treatment
response was defined by WHO criteria, with the
extent of tumor necrosis being seen as mass re-
duction. A complete response (CR) was defined as
complete disappearance of staining on angio-
graphic evaluation and as complete necrosis with-
out a viable portion on spiral CT scan. A partial
response (PR) was defined as 50% decrease in
the sum of the bidimensional measurements in
both studies. CR duration was defined from the
time of CR achievement to disease recurrence. If
CT scans obtained at 1 month showed persistence
of residual tumor, or if the tumor relapsed on
follow-up study, an additional treatment, such as
TACE or transarterial chemoinfusion (TACI), was
performed at the physician's discretion. Adverse
events were assessed using NCI-CTC software
(version 2.0).
RESULTS
Patient characteristics
Between November 1999 and January 2004, a
Table 1. Dose to the Tumor by Trans-arterial Injection of 166Holmium-Chitosan Complex
No Diameter (cm) Injection (mCi) Mean dose (Gy) Central dose* (Gy) Peripheral dose (Gy)
1 1.5 30 7668 9222 7061
2 1.5 30 7668 9222 7061
3 1.5 30 7668 9222 7061
4 1.8 30 4599 5314 4178
5 2 30 3401 3887 3062
6 2 30 3401 3887 3062
7 2 30 3401 3887 3062
8 2 40 4535 5182 4083
9 2 50 5669 6478 5104
10 2.3 30 2286 2558 2041
11 2.5 30 1800 2001 1591
12 2.5 30 1800 2001 1591
*Central dose is the average value over the remaining inner part of tumor.
Peripheral dose is the average value over the outer 2.5 mm-thick part of tumor.
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total of 12 patients (9 men and 3 women) entered
the study. All patients were diagnosed with HCC
on a clinical basis, and were referred to interven-
tional radiology for initial therapy. All patients,
except one with Child-Pugh C liver cirrhosis, had
operable HCC at the time of diagnosis, however
refused surgery. The median follow-up duration
was 26 (range: 12-61) months. The patient charac-
teristics are listed in Table 2. The median patient
age was 55 (range: 39-72) years. Of the 12 patients,
8 and 4 had HBV or HCV- related HCC, respec-
tively. Liver cirrhosis was present in 4 patients (3
Child-Pugh A, 1 Child-Pugh C); there was no
clinical evidence of liver cirrhosis in the other
patients. All patients except one had an ECOG
performance status of 0 or 1. The median pretreat-
ment AFP level was 84 ng/mL (range: 3-564). The
median tumor size was 2.0 cm (range: 1.5-2.5). In
5 patients, the tumor was located on the liver
dome.
Efficacy and safety results
The median dose of 166Holmium-Chitosan com-
plex administered was 30 mCi (range, 30-50). All
patients received a planned dose of 20 mCi/mL
per cm of tumor diameter. Treatment caused
tumors to appear necrotic on CT scan and to
appear avascular on angiography (Fig. 1 and 2).
CR was seen in 10 patients (83%), 2 experienced
relapse at 6 and 17 months, respectively; both
patients received further treatment with TACI and
thereafter, remained disease-free for 25 months
and 4 months. Median CR duration was not
reached. PR was seen in 2 patients (17%), they
received additional treatments with TACE. In one
patient, additional TACE provided CR and a
disease free state thereafter. Of all the patients, 10
are currently alive. One patient, who initially
presented as Child-Pugh C liver cirrhosis and
showed CR, died of advanced liver cirrhosis 18
months after treatment. The cause of death did
not appear to be related to the treatment. The
other death was in a patient showing PR, who
died of tumor progression 51 months after treat-
ment.
In all patients, AFP levels fell between 99 to
17% of the pretreatment levels (Fig. 3). A drop of
50% or more occurred in 8 of 12 patients. The
greatest drop of 99% occurred in a 54 year old
female with a 2 cm tumor; she is still alive without
recurrence with a follow-up period of 34 months.
The median AFP level dropped from 83.8 to 8.3
ng/mL within 2 months after treatment.
The biodistribution following the trans-arterial
administration of the complex demonstrated that
Table 2. Patients Characteristics
No
Sex/Age
(yrs)
Size
(cm)
Tumor
site Cirrhosis*
Response
Dose
(mCi)
AFP decrease
(%)
Relapse
Next
treatment
Survival (months)
1 F/55 1.5 S8D A PR 30 22 No TACE 51
2 M/61 1.5 S8D No CR 30 53 No Alive (FU 61)
3 M/39 1.5 S8D No CR 30 94 Yes TACI Alive (FU 21)
4 M/72 1.8 S7 No CR 30 25 No Alive (FU 33)
5 M/61 2 S8D A CR 30 23 Yes TACI Alive (FU 31)
6 M/67 2 S8D No CR 30 81 No Alive (FU 34)
7 M/43 2 S3 C CR 30 97 No 18
8 M/58 2 S7 No CR 40 98 No Alive (FU 12)
9 F/54 2 S7 No CR 50 99 No Alive (FU 34)
10 M/46 2.3 S7 No CR 30 17 No Alive (FU 15)
11 M/50 2.5 S8 A PR 30 70 No TACE Alive (FU 14)
12 F/44 2.5 S8 No CR 30 84 No Alive (FU 19)
*Child-Pugh classification.
S, segment of liver; D, liver dome area; CR, complete response; PR, partial response; TACE, trans-arterial chemoembolization; TACI,
trans-arterial chemoinfusion; FU, follow-up period.
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most of the injected radioactivity localized within
the liver and that the extra-hepatic leakage was
negligible at 24 hours after treatment (Fig. 4).
In our study, no grade III to IV toxicity was
observed in terms of hematologic and nonhe-
matologic toxicities. Only grade I to II nonhema-
tologic toxicities, including two abdominal pain of
grade II, one fever of grade I, and one AST/ALT
elevation of grade I, were observed. They required
only supportive care. No toxic death occurred.
DISCUSSION
The use of intra-arterially administered radio-
nuclide for treatment of HCC has the potential to
overcome the disadvantages of external beam
radiation, which is currently limited by the radio
Fig. 1. CT scan (A) and angiography (B) of a 2 cm hypervascular HCC (arrow) before trans-arterial
166
Holmium-Chitosan
complex.
Fig. 2. CT scan (A) and angiography (B) showing complete tumor response 4 weeks after treatment.
Fig. 3. AFP level changes in all patients (n = 12), within the
2 months after
166
Ho treatment.
A B
A B
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sensitivity of healthy tissue. Selective internal
radiation treatment with 90Yttrium microspheres
has been used as palliative treatment of inoper-
able HCC or metastatic liver tumors.12,13 However,
the currently used radioactive 90Yttrium micro-
spheres cannot be visualized directly with scin-
tigraphy because 90Yttrium is a pure beta emitter.
For this reason, estimation of arterio-venous
shunting by Tc-MAA scan is required in order to
avoid serious complications, such as radiation
pneumonitis and gastrointestinal bleeding.14
To overcome this major drawback, radioactive
166Ho was used in our study; it emits both gamma
rays for diagnostic scintigraphic imaging and beta
particles for therapy. Since holmium is paramag-
netic, it can also be visualized clearly with MR
imaging. Furthermore, production of
166
Ho is sim-
ple and less expensive compared with 90Y or other
radionuclides, since it comes from a naturally
abundant element. Several preclinical studies have
shown that intra-arterial administration of 166Hol-
mium poly (L-lactic acid) microspheres has
potential for internal radiation therapy of HCC.
4-6
Instead of using poly lactic acid microsphere as
a vehicle, we used chitosan in our study. Chitosan,
a polymer of 2-deoxy-2-amino-D-glucose obtained
by deacetylation of chitin, forms a chelate with
heavy metals. One major advantage of using
chitosan as a carrier is its variable viscosity, which
depends on the environmental pH. That is,
chitosan dissolves in water to make a clear solu-
tion under acidic conditions, but converts to a gel
state under basic conditions.9 This unique charac-
teristic confers superiority over other delivery
systems, because chitosan functions not only as a
drug delivery system, but also through the em-
bolization effect on the tumor's feeding arteriole.
In a phase I/IIa clinical trial, 166Ho-chitosan com-
plex was injected percutaneously into a small
HCC, resulting in 77.5% complete tumor necrosis
and minimal toxicity.15 With this in mind, we
conducted the pilot study to evaluate the clinical
efficacy of transarterial administration of
166Holmium-Chitosan complex in patients with a
single and small (< 3 cm) HCC. In our study, all
patients with advanced liver cirrhosis, except one,
had resectable HCC but refused surgery.
The main findings of this study are that 83% of
patients showed CR and 17% showed PR. This
response rate is quite comparable to PEI or RFA.
Although both percutaneous treatments provide
CR in 80 to 90% of patients, they are highly de-
pendent on the practitioner's skills and tech-
niques. Furthermore, several treatment sessions
are required to achieve a high response rate.2,3 Of
5 tumors in the liver dome, 4 showed CR. This
analysis is important because percutaneous ap-
proach to the liver dome is difficult and treat-
ments are usually considered unsafe in these
patients.
A major concern regarding trans-arterial radio-
therapy is radionuclide leakage into the systemic
circulation. Pharmacokinetic study showed that
166Ho itself cannot be retained in the administra-
tion site, unless it is in a chelated complex with
chitosan.
16
Furthermore, distribution of the radio-
activity in tissues, determined by gamma camera,
confirmed that most administered radioactivity
was retained in the tumor.
Localization of the catheter tip in the super-
selected artery that directly feeds the tumor,
instead of the hepatic artery proper, increased the
selectivity of treatment. In our study, no patients
developed radiation-induced pneumonitis or gas-
tritis, which can result from significant shunting
to the lung or upper gastrointestinal tract. This
was likely due to the fact that patients with vas-
cular shunts were excluded and because of super
selection of the tumor-feeding artery.
The minimal radionuclide leakage and super
selection of the tumor-feeding artery seemed to be
Fig. 4. Gamma scan obtained immediately after treatment
shows
166
Holmium-Chitosan complex retained within tu-
mor mass.
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translated into an absence of serious systemic
toxicities in our patients. Mild postembolization
syndrome, characterized by fever and abdominal
pain, was the only adverse event of this treatment.
According to the Monte-Carlo code simulation
technique, a dose of 20 mCi 166Ho per cm of tumor
diameter was predetermined to expose the normal
tissue, in a 3 mm radius, to a radiation dose of 100
Gy. Unfortunately, a volume-based dose escala-
tion could not be evaluated because the drug was
too viscous to administer as a large amount.
Because of this characteristic, along with toxicity
concern the dose was increased according to
increasing diameter (20 mCi/cm), but not to tu-
mor volume.
In conclusion, the results of this study demon-
strate that trans-arterial 166Holmium-Chitosan
complex administration is an effective treatment
option with acceptable toxicities for small HCC
(< 3 cm). The high CR rate may permit this treat-
ment as one of the curative treatment modalities.
However, further trials in a larger patient popula-
tion are warranted, in order to evaluate the
therapeutic efficacy of the 166Holmium-Chitosan
complex.
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